Csehi R, Dombi ZB, Sebe B, Molnar MJ. Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies. Front Psychiatry 2022;13:827744. https://www.ncbi.nlm.nih.gov/pubmed/35370825
Durgam S, Earley W, Li R, Li D, Lu K, Laszlovszky I, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res 2016;176(2-3):264-71. https://www.ncbi.nlm.nih.gov/pubmed/27427558
Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2015;17(1):63-75. https://www.ncbi.nlm.nih.gov/pubmed/25056368
Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 2014;152(2-3):450-7. https://www.ncbi.nlm.nih.gov/pubmed/24412468.
Findling RL, Cavus I, Pappadopulos E, Vanderburg DG, Schwartz JH, Gundapaneni BK, et al. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol 2013;23(8):531–44. https://www.ncbi.nlm.nih.gov/pubmed/24111983
Generoso MB,
Taiar I, Cordeiro Q, Shiozawa P, Kasper S. Cariprazine for treating psychosis:
an updated meta-analysis. Int J Psychiatry Clin Pract 2023;27(1):107-9.
https://www.ncbi.nlm.nih.gov/pubmed/35544479
Grunder G, Heinze M, Cordes J, Muhlbauer B, Juckel G, Schulz C, et al. Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry 2016;3(8):717–29. https://www.ncbi.nlm.nih.gov/pubmed/27265548
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012;13(5):318–78. https://www.ncbi.nlm.nih.gov/pubmed/22834451
Kane JM, Zukin S,
Wang Y, Lu K, Ruth A, Nagy K, et al. Efficacy and Safety of Cariprazine in
Acute Exacerbation of Schizophrenia: Results From an International, Phase III
Clinical Trial. J Clin Psychopharmacol 2015;35(4):367-73.
https://www.ncbi.nlm.nih.gov/pubmed/26075487
Krause M, Zhu Y,
Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy,
acceptability, and tolerability of antipsychotics in children and adolescents
with schizophrenia: A network meta-analysis. Eur Neuropsychopharmacol
2018;28(6):659-74. http://www.ncbi.nlm.nih.gov/pubmed/29802039
Marder S,
Fleischhacker WW, Earley W, Lu K, Zhong Y, Nemeth G, et al. Efficacy of
cariprazine across symptom domains in patients with acute exacerbation of
schizophrenia: Pooled analyses from 3 phase II/III studies. Eur
Neuropsychopharmacol 2019;29(1):127-36.
https://www.ncbi.nlm.nih.gov/pubmed/30470662
National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management [cg178]. London: NICE; 2014. https://www.nice.org.uk/guidance/cg178
Yeisen RAH, Bjornestad J, Joa I, Johannessen JO, Opjordsmoen S. Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study. BMC Psychiatry 2017;17(1):299. https://www.ncbi.nlm.nih.gov/pubmed/28830453
Zhu Y, Krause M, Huhn M, Rothe P, Schneider-Thoma J, Chaimani A, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 2017;4(9):694–705. https://www.ncbi.nlm.nih.gov/pubmed/28736102
